Singapore Cancer Diagnostic RNA Technology Firm Mirxes Holding to Raise $139 Million at $819 Million Valuation in Hong Kong IPO with Expected Listing on 23rd May 2025, Filed for Hong Kong IPO in 2nd Application after 1st Filing in 2023 July, Secured $50 Million Series D Funding in 2023, Mirxes was Spin-off from Singapore Agency of Science, Technology & Research in 2014, Reported $56.6 Million Loss in 2022, $69.2 Million Loss in 2023 & $92.3 Million Loss in 2024
16th May 2025 | Hong Kong
Singapore cancer diagnostic RNA technology firm Mirxes Holding is raising $139 million at $819 million valuation in Hong Kong IPO with expected listing on 23rd May 2025. In 2024 May, Mirxes Holding filed for a Hong Kong IPO in 2nd application after 1st filing in 2023 July, targeting to raise $100 million at $600 million valuation in the IPO. In 2023 July, Mirxes Holding had announced securing $50 million in Series D funding. Mirxes was spin-off from Singapore Agency of Science, Technology & Research in 2014 (A*STAR). Mirxes Holding reported $56.6 million loss in 2022, $69.2 million loss in 2023 & $92.3 million loss in 2024. Mirxes Holding – We are a Singapore-headquartered RNA technology company that is a pioneer and leader in developing and commercializing accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Our story began in early 2000s when our founders pioneered a highly sensitive, specific and robust detection technology for microRNA (miRNA), the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic, and infectious diseases, we decided to bring our technology from lab to clinic. In 2014, we spun off from Agency of Science, Technology and Research (A*STAR) to commercialise our technology and develop accurate multi-cancer early detection solutions and make them readily available and accessible to people who need them. We believe that the future of healthcare will shift from treating the sick to preventive healthcare. Our science and innovation will continue as we are committed to making diagnostic solutions for the early detection of diseases accessible on a global scale.
” Singapore Cancer Diagnostic RNA Technology Firm Mirxes Holding to Raise $139 Million at $819 Million Valuation in Hong Kong IPO with Expected Listing on 23rd May 2025, Filed for Hong Kong IPO in 2nd Application after 1st Filing in 2023 July, Secured $50 Million Series D Funding in 2023, Mirxes was Spin-off from Singapore Agency of Science, Technology & Research in 2014, Reported $56.6 Million Loss in 2022, $69.2 Million Loss in 2023 & $92.3 Million Loss in 2024 “
Singapore Cancer Diagnostic RNA Technology Firm Mirxes Holding Files for Hong Kong IPO in 2nd Application after 1st Filing in 2023 July, Target to Raise $100 Million at $600 Million Valuation, Secured $50 Million Series D Funding in 2023, Mirxes was Spin-off from Singapore Agency of Science, Technology & Research in 2014
9th May 2024 – Singapore cancer diagnostic RNA technology firm Mirxes Holding has filed for a Hong Kong IPO in 2nd application after 1st filing in 2023 July, targeting to raise $100 million at $600 million valuation in the IPO. In 2023 July, Mirxes Holding had announced securing $50 million in Series D funding. Mirxes was spin-off from Singapore Agency of Science, Technology & Research in 2014 (A*STAR). Mirxes Holding – We are a Singapore-headquartered RNA technology company that is a pioneer and leader in developing and commercializing accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Our story began in early 2000s when our founders pioneered a highly sensitive, specific and robust detection technology for microRNA (miRNA), the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic, and infectious diseases, we decided to bring our technology from lab to clinic. In 2014, we spun off from Agency of Science, Technology and Research (A*STAR) to commercialise our technology and develop accurate multi-cancer early detection solutions and make them readily available and accessible to people who need them. We believe that the future of healthcare will shift from treating the sick to preventive healthcare. Our science and innovation will continue as we are committed to making diagnostic solutions for the early detection of diseases accessible on a global scale.
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
